Stockscreener 앱 받기
4.22
4.31%
-0.19
시간 외 거래:
4.19
-0.03
-0.71%
Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스
Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody CandidatesSlideshow (NASDAQ:ACRS) 2026-04-28 - Seeking Alpha
Aclaris Therapeutics Updates ATI-052 Phase 1 Data, Picks ATI-2138 for Phase 2b in Lichen Planus - Yahoo Finance
Aclaris Posts Strong Phase 1a ATI-052 Data, Sets Lichen Planus As Lead Indication For ATI-2138 - RTTNews
Aclaris Therapeutics says positive full top line results from Phase 1a clinical trial of ATI-055 - marketscreener.com
Aclaris Reports Positive ATI-052 Phase 1a Trial Results - TipRanks
Aclaris reports phase 1a trial results for ATI-052 antibody By Investing.com - Investing.com Canada
Aclaris Therapeutics announced that the Phase 1B clinical trial of its drug candidate ATI-052 is currently actively recruiting patients. - Bitget
Aclaris (NASDAQ: ACRS) touts ATI-052 data, targets lichen planus with ATI-2138 - Stock Titan
Aclaris targets lichen planus, a disease with no approved therapies - Stock Titan
Aclaris Therapeutics Insider Sold Shares Worth $1,359,000, According to a Recent SEC Filing - marketscreener.com
Leonard Braden Michael sells $1.36m in Aclaris Therapeutics stock - Investing.com
Aclaris Therapeutics (NASDAQ: ACRS) insider-linked fund sells 300,000 shares - Stock Titan
BML Investment lists 13.95M shares (9.9%) in Aclaris (NASDAQ: ACRS) - Stock Titan
Aclaris to release ATI-052 trial data, ATI-2138 update Tuesday By Investing.com - Investing.com Canada
Aclaris Therapeutics to Announce Phase 1a Trial Results for ATI-052 and Lead Indication Selection for ATI-2138 on April 28, 2026 - Quiver Quantitative
What Aclaris will reveal Tuesday on two immune-disease drug programs - Stock Titan
Aclaris Therapeutics (ACRS) Piper Sandler 36th Annual Healthcare Conference Summary - Quartr
Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 - Sahm
Aclaris Therapeutics (ACRS) Proxy filing Summary - Quartr
Aclaris Therapeutics (NASDAQ:ACRS) Shares Gap DownHere's What Happened - MarketBeat
Aclaris Therapeutics, Inc. ($ACRS) CEO 2025 Pay Revealed - Quiver Quantitative
Executive pay, board elections in Aclaris Therapeutics (NASDAQ: ACRS) 2026 proxy - Stock Titan
Aclaris Therapeutics Advances Immuno-Inflammatory Pipeline, Targets Four Clinical Programs in 2026 - MSN
Aclaris (ACRS) Stock Gap Down Watch (Investor Interest) 2026-04-20Stock Analysis Community - Cổng thông tin điện tử tỉnh Lào Cai
Oppenheimer Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $10 - Moomoo
Craig-Hallum Maintains Aclaris Therapeutics(ACRS.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Oppenheimer initiates coverage of Aclaris Therapeutics (ACRS) with outperform recommendation - MSN
ACRS Initiated Coverage by Oppenheimer -- Rating Set to Outperfo - GuruFocus
Oppenheimer Initiates Aclaris Therapeutics at Outperform With $10 Price Target - Moomoo
Oppenheimer initiates Aclaris stock with Outperform rating By Investing.com - Investing.com Australia
Oppenheimer initiates Aclaris stock with Outperform rating - Investing.com
H.C. Wainwright reiterates Aclaris stock rating on drug trial data By Investing.com - Investing.com Canada
Aclaris (ACRS) Stock: Momentum Shift (Marginal Gain) 2026-04-15Fast Rising Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Aclaris Therapeutics Touts ATI-052 Potential for 3-Month Dosing, More Phase 1 Data Incoming - Yahoo Finance
Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Increases By 49.4% - MarketBeat
Market Overview: What is the implied volatility of Aclaris Therapeutics Inc2026 Technical Patterns & Daily Growth Stock Tips - baoquankhu1.vn
Is Aclaris (ACRS) Stock Attractive Now | Price at $4.00, Down 1.11%Turnaround Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Pullback Watch: Will Aclaris Therapeutics Inc benefit from AI trends2026 Buyback Activity & Consistent Income Trade Ideas - baoquankhu1.vn
ACRS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference - Sahm
Is Aclaris (ACRS) Stock Near a Bottom | Price at $3.98, Up 0.76%Price Surge - Xã Châu Thành
Aclaris Therapeutics, Inc. (ACRS) stock price, news, quote and history - Yahoo Finance UK
Aclaris Therapeutics Earns 'Moderate Buy' Rating from Analysts - National Today
RA Capital Group reports 7.63M Aclaris shares (NASDAQ: ACRS) - Stock Titan
Forecast Cut: Why is Aclaris Therapeutics Inc stock going upMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
ACRS PE Ratio & Valuation, Is ACRS Overvalued - Intellectia AI
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded at Wall Street Zen - MarketBeat
ACRS Stock Analysis: Aclaris Therapeutics Inc biotech stock gains 1.45 percent at 4.2 dollars - UBND thành phố Hải Phòng
Aug Macro: Is Bit Digital Inc a top pick in the sector2026 Reactions & Consistent Growth Equity Picks - baoquankhu1.vn
ACRS SEC FilingsAclaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aclaris Therapeutics (NASDAQ:ACRS) Trading Up 10.2%What's Next? - MarketBeat
Aclaris to present phase 2a ATI-2138 data at dermatology meeting - MSN
Aclaris completes enrollment in phase 2 trial of Bosakitug for atopic dermatitis - MSN
Aclaris Therapeutics' (ACRS) Outperform Rating Reaffirmed at Wedbush - MarketBeat
Aclaris Therapeutics (NASDAQ:ACRS) Shares Pass Below 50 Day Moving AverageShould You Sell? - MarketBeat
0.29%
0.00%
자본화:
|
볼륨(24시간):